Caplin Point Laboratories Ltd is engaged in the manufacturing and sourcing of APIs, finished formulations, R&D, clinical research with presence in Latin America, Africa, USA and other nations.
Financial Results:
Caplin Point Laboratories Ltd reported Revenues for Q4FY24 of ₹453.00 Crores up from ₹389.00 Crore year on year, a rise of 16.45%.
Total Expenses for Q4FY24 of ₹324.00 Crores up from ₹276.00 Crores year on year, a rise of 17.39%.
Consolidated Net Profit of ₹121.00 Crores up 19.8% from ₹101.00 Crores in the same quarter of the previous year.
The Earnings per Share is ₹16.01, up 19.03% from ₹13.45 in the same quarter of the previous year.
*It is important to note that the way the results have been accounted for are slightly different than the ones the companies may choose to publish.
*The presented data is automatically generated. It may occasionally generate incorrect information.